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Porcine bioprostheses are physiologically stenotic valves. 
Degenerative calcification leading to pathologic stenosis 
is an increasingly recognized serious late complication 
of mitral valve replacement with a porcine bioprosthesis. 
Hemodynamic differentiation of patl\ologic from phys•
iologic stenosis is important for identification of porcine 
bioprosthetic valve dysfunction. In 42 patients with a 
normal Hancock porcine bioprosthesis (standard model, 
sizes 27 to 33 mm), mean diastolic flow (65 to 461 mIls), 
mean gradient (2.0 to 13.4 mm Hg) and effective orifice 
area (1.1 to 4.4 cm2) were determined at rest, during 
epicardial pacing (90, 110 and 130/min) and with iso•
proterenol infusion. A statistically significant increase in 
mean gradient occurred with increases in flow and de•
creases in valve size (p < 0.05). Effective orifice area 
increased significantly as flow rate increased and as valve 
size increased (p < 0.05). 
These measurements were compared with those in 16 
patients with pathologically confirmed porcine biopros•
thetic valve stenosis: 8 patients with reoperation (1.1 % 
per patient-year) 3 to 8.S years after mitral valve re•
placement and 8 previously reported abnormal cases. 
Glutaraldehyde-preserved porcine bioprostheses are exten•
sively utilized as cardiac valve substitutes because of low 
thrombogenicity and avoidance of long-term anticoagulation 
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Stenotic failure rate was inversely related to valve size 
(2.1, 1.4, 0.5 and 0% per patient-year for sizes 27 to 33 
mm). Stenotic and normal bioprostheses were not ac•
curately differentiated on the basis of a single value for 
gradient or effective orifice area. A mathematical model 
that related flow to the square root of the mean gradient 
allowed complete separation of stenotic from normal 
prosthetic valve function, after valve size was accounted 
for and normal confidence limits were established (r = 
0.74 to 0.94, sizes 27 to 33, p < 0.0001). The effective 
orifice area-flow relation did not provide accurate dif•
ferentiation of abnormal from normal function. 
Thus, normal mitral bioprostheses have significant 
trans valvular gradients whose magnitude depends on 
flow. Risk of stenotic failure is increased in the smaller 
valves, which have a larger gradient at implantation. 
Differentiation of pathologic from physiologic stenosis 
cannot be made on the basis of a single value for gradient 
or effective orifice area. Accurate hemodynamic differ•
entiation is achieved by relating mean gradient to mean 
diastolic flow rate and valve size. 
(J Am Coli CardioI1986;7:284-94) 
in most patients. The major shortcoming of bioprostheses 
is their limited durability (1-3), which may be manifested 
by stenosis, regurgitation or a combination of both (4-13). 
Prosthetic valve dysfunction due to stenosis is an increas•
ingly recognized late complication after porcine valve re•
placement, but recognition of stenosis may be difficult be•
cause a significant transvalvular gradient has been observed 
across normal bioprostheses (14-27). 
The present study was undertaken to compare the relative 
hemodynamic performance of normal and stenotic mitral 
Hancock bioprostheses, and to determine whether reliable 
hemodynamic differentiation of pathologic from physiologic 
stenosis could be achieved. In addition, we attempted to 
determine whether the hemodynamic performance of smaller 
valve sizes affected long-term stenotic failure rates. 
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Methods 
Patients with a normal bioprosthesis. Forty-two con•
secutive patients undergoing mitral valve replacement with 
a standard Hancock porcine bioprosthesis (model 342, sizes 
27 to 33 mm) were studied within 24 to 48 hours after 
surgery. Matched length 18 gauge, fluid-filled polyvinyl 
catheters were placed surgically into the left atrium and left 
ventricle and were connected to identically calibrated pres•
sure transducers (Honeywell model 4-327-1). Postopera•
tively. after stabilization and complete rewarming of the 
patient in the intensive care unit, hemodynamic measure•
ments were performed. These included simultaneous left 
atrial and left ventricular pressures, cardiac output (by ther•
modilution), heart rate and diastolic filling period at rest. 
Measurements were repeated during epicardial atrial pacing 
(ventricular in three patients) at rates of 90. 110 and 130 
beats/min, and after intravenous isoproterenol infusion (con•
centration 8 j.Lg/ml) at a dose sufficient to increase the heart 
rate to 120 beats/min (28). The average dose of isoproterenol 
used was 0.04 j.Lg/kg per min. Pressures were recorded with 
an Electronics for Medicine VR6 recorder utilizing Iight•
sensitive paper at 100 mm/s. In these 42 normal subjects. 
a total of 169 studies were performed (mean 4 studies per 
patient). 
Patients with a stenotic bioprosthesis. Of 209 consec•
utive patients who underwent Hancock porcine mitral valve 
replacement (model 342, sizes 27 to 33 mm) at Cedars•
Sinai Medical Center between 1976 and 1982 and were 
followed up prospectively for 1 to 100 months (mean 41), 
8 (4%) developed worsening symptoms and a new diastolic 
murmur suggestive of bioprosthetic valve stenosis. Each of 
these patients underwent cardiac catheterization. 
Simultaneous left ventricular and pulmonary capillary 
wedge pressures (corrected for phase delay), cardiac output 
(by thermodilution), heart rate and diastolic filling period 
were measured at rest and with trans venous atrial pacing at 
110 beats/min or with isoproterenol infusion (8 j.Lg/ml at a 
dose sufficient to increase heart rate to 120 beats/min) if 
these interventions were deemed clinically safe. In these 
eight patients. 15 studies were performed (mean 2 studies 
per patient). 
An additional group of eight patients with mitral Hancock 
bioprosthetic valve stenosis and corresponding cardiac 
catheterization data were obtained by a review of the lit•
erature (29-34). In this group eight studies were available. 
Thus. in a total of 16 patients with a stenotic prosthesis (8 
of our own and 8 from published reports), 23 hemodynamic 
studies were available. All 16 patients underwent reopera-
T~ble 1. Hemodynamic Data at Baseline and After Interventions in 42 Patients With a Normal Hancock Mitral Bioprosthesis 
(SIZes 27 to 33 mm) 
Intervention 
Pacmg Pacing Pacing 
BaselIne (90/mm) (lIO/mm) (l30/min) Isoproterenol 
Hemodynamic Vanable (n = 51) (n = 34) (n = 35) (n = 29) (n - 20) 
Mean diastolIc flow (mils) 
Mean ± SD 138 ± 49 160 ± 43 201 ± 45* 230 ± 52* 289 ± 85* 
Range 65 to 251 88 to 271 121 to 3m 137 to 375 157 to 461 
Mean gradient (mm Hg) 
Mean ± SD 3.6 ± 1.8 37 ± 1.4 5.6 ± 2.1* 7.1 ± 2.3* 7 8 ± 3.0* 
Range 2.0 to 8.4 2.0 to 7 2 2.0 to 105 4.0 to 13.0 20 to 13.4 
Effective orifice area (em') 
Mean ± SD 1.95 ± 0.50 2.25 ± 0.55* 2.32 ± 0.58* 2.32 ± 054* 2.82 ± 0.76* 
Range 1 10 to 3 46 1.24 to 3.72 1 64 to 3.89 1.63 to 4.00 1.82 to 4 40 
Stroke volume (ml) 
Mean ± SD 50 ± 12 46 ± \I 41 ± 9* 34 ± 6* 64 ± 16*t 
Diastolic filling penod (seconds/beat) 
Mean ± SD 0.39 ± 0 II 0.29 ± 0.04* 021 ± 003* 0.15 ± 0.03* 0.23 ± 006*t 
Heart rate (min - I) 
Mean ± SD 80 ± 16 90 ± 2* 110 ± 4* 129 ± 3* 118 ± 20* 
Rhythm 
Sinus 32 0 0 0 13 
Atnal fibrillatIOn \I 0 0 0 5 
Atnal-paced 8 31 33 27 2 
Ventricular paced 0 3 2 2 0 
Left atrial pressure (mm Hg) 
Mean ± SD 13.2 ± 4.1 15.5 ± 4.6 16.2 ± 4.7* 16.7 + 4.2* 15.3 + 4.5 
*p < 0 OS, compared with baseline value; tp < 0 OS, Isoproterenol for pacmg at l30/mm. 
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tion, explantation and pathologic examination of the bio•
prosthetic valve, with confirmation of pathologic stenosis 
in each patient. 
Etiologic classification of stenosis. The cause of the 
bioprosthetic valve stenosis was determined from gross an•
atomic, microscopic and radiographic examination of the 
excised prosthesis (4-11) . Calcification was considered to 
be the cause of stenosis if multiple firm, nodular masses 
(~ 2 mm) adherent to the leaflet base, body or edge of all 
three leaflets and resulting in restricted leaflet excursion 
were identified. Histologic and ex vivo radiographic evi•
dence of calcification was judged confirmatory. 
Fibrous tissue overgrowth was identified as the cause of 
stenosis if the inflow orifice of the anulus was covered by 
a layer of connective tissue that extended at least 2 mm onto 
the base of all three leaflets, reducing the size of the inflow 
orifice and restricting leaflet mobility. Frequently, the out•
flow surface of the leaflet was covered by fibrous tissue as 
well. Microscopic findings of a collagenous sheath that cov•
ered relatively normal-appearing leaflet tissue was judged 
confirmatory. 
Prosthetic valve thrombosis was considered to be the 
cause of stenosis if a thrombus adherent to the inflow surface 
of a leaflet produced orifice narrowing, or if the thrombus 
was identified on the outflow surface of the leaflet and re•
sulted in restriction of leaflet mobility. Inward stent bending 
was considered the cause of stenosis if the polypropylene 
stents were bent inward, producing orifice narrowing (29). 
Calculations. Mean diastolic pressure gradient (G) was 
determined from the area, measured by planimetry. between 
the simultaneous diastolic left ventricular and left atrial (or 
phase-corrected pulmonary capillary wedge) pressures, di•
vided by the diastolic filling period per beat (defined by the 
crossover of left atrial and left ventricular pressures). In the 
presence of atrial fibrillation, the mean gradient was aver•
aged over 10 beats. 
Mean diastolic flow (mils) was calculated from the car•
diac output (CO), heart rate (HR) and diastolic filling period 
per beat (DFP) according to the formula: mean diastolic 
flow = CO/(HR x DFP). 
Effective orifice area (EOA) was calculated from the Gor•
lin relation according to the formula: EOA = mean diastolic 
flow/(38 x Va). 
Statistical methods. Values of continuous variables are 
expressed as mean ± SD. Comparisons between continuous 
variables for two groups were made with the unpaired two•
tailed t test. Comparisons among continuous variables for 
three or more groups were made with Friedman's nonpar•
ametric analysis of variance. and pairwise comparisons uti•
lized the Wilcoxon signed-rank test with alpha levels ad•
justed by applying the Bonferroni correction. Comparisons 
across flow ranges and valve sizes were made using Kruskal•
Wallis one-way analysis of variance; differences were iso•
lated using Fisher's least significant difference method ap-
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plied to ranks. Discrete variables were compared by means 
of chi-square analysis or Fisher's exact test. For all uni•
variate analyses, the alpha level was set at 0.05. Linear 
regression analysis was performed by the methods of least 
squares. All statistical calculations were performed by BMDP 
statistical software (35-37). 
Results 
Normal Bioprostheses 
Diastolic flow, diastolic gradient and effective orifice 
area (Table 1). At the baseline level of mean diastolic flow 
(138 ± 49 mIls; range 65 to 251). the mean diastolic pres•
sure gradient was 3.6 ± 1.8 mm Hg (range 2.0 to 8.4) and 
the effective orifice area was 1. 95 ± 0.50 cm2 (range 1.10 
to 3.46). To extend the range of flows over which obser•
vations were made, measurements were repeated with epi•
cardial pacing at incrementally increasing rates and after 
infusion of isoproterenol. At paced rates of 110 and 130 
beats/min, there was a statistically significant increase in 
mean diastolic flow. mean gradient and effective orifice area 
compared with values at rest (p < 0.05). Mean diastolic 
flow increased despite a decrease in stroke volume and this 
increase was associated with marked shortening of the di•
astolic filling period (p < 0.05). Pacing at 90 beats/min 
produced an intermediate response. 
Figure 1. Influence of valve size and flow rate on mean diastolic 
pressure gradient. There was a statistically significant decrement 
in gradient from the smallest (27 mm) to the largest (33 mm) valve 
size at each flow interval (50 to 150, 151 to 250 and 251 to 350 
mils). For each valve size there was a significant increase in gra•
dient with increasing flow. Asterisk indicates a statistically sig•
nificant difference when compared with the gradient at a flow rate 
of 50 to 150 mils. 
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Figure 2. Gradient-flow relation in normal Hancock bio•
prostheses, stratified by valve size. Solid line connects mean pres•
sure gradients measured across an individual valve at different 
flow rates produced by varying conditions (symbols). In general, 
mean gradient increased as flow increased, This increase was least 
pronounced in the largest valve size (33 mm). 
Isoproterenol (average dose 0,04 J.Lglkg per min) produced 
the largest mean diastolic flow (289 ± 85 mIls), gradient 
(7.8 ± 3.0 mm Hg) and effective orifice area (2.82 ± 0.76 
cm2). These values were somewhat larger than, but statis•
tically not different from, those obtained with pacing at 130 
beats/min. With isoproterenol, the increase in mean diastolic 
flow was associated with an increase in stroke volume and 
a lesser shortening of the diastolic filling period compared 
with the value during pacing at 130 beats/min (p < 0.05) 
(Table 1). 
Gradient-flow relation. Because interventions that in•
creased flow were associated with concomitant increases in 
gradient (Table 1), we investigated more closely this cor•
relation and its relation to valve size. A statistically signif•
icant (p < 0.05) difference in mean gradient was observed 
between the smallest (27 mm) and largest (33 mm) valve 
size at each of three defined flow intervals (Fig. 1). For 
each valve size, there was a statistically significant increase 
Figure 3. Influence of valve size and flow rate on effective orifice 
area. There was a statistically significant increase in effective ori•
fice area from the smallest (27 mm) to the largest (33 mm) valve 
size at each flow interval (50 to 150. 151 to 250 and 251 to 350 
mils). For each valve size there was a significant increase in ef•
fective orifice area with increasing flow, Asterisk indicates a sta•
tistically significant difference when compared with effective ori•
fice area at a flow rate of 50 to 150 mils. 
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in mean gradient at medium (150 to 250 mils) and high 
(250 to 350 mils) flow rates, compared with the gradient at 
a low flow rate (50 to 150 mils). Thus, the mean gradient 
across a normal bioprosthesis was substantially influenced 
by both flow rate and valve size. 
This effect was confirmed on an individual basis (Fig. 
2). Interventions that increased flow generally increased 
mean gradient, but to a much lesser extent in larger valves. 
The largest valve (33 mm) had the largest maximal flows 
(400 to 500 mils) with the smallest gradients. Additionally, 
the largest flows were observed in the largest valves. 
Effective orifice area-flow relation. Effective orifice 
area, calculated according to the Gorlin relation, differed 
significantly in the smallest and largest valves (Fig. 3). For 
each valve size there was a statistically significant (p < 
0.05) increase in the effective orifice area at medium (150 
to 250 mils) and high (250 to 350 mils) flows, compared 
with that at a lower flow rate (50 to 150 mils). On an 
individual basis interventions that increased flow led in most 
cases to an increase in effective orifice area (Fig. 4). A 
linear regression model confirmed a statistically significant 
correlation between effective orifice area and valve flow 
(r = 0.55 to 0.89, P < 0.001 for each valve size) (Fig. 5). 
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Stenotic failure rate (Table 2). In our entire series of 
patients with mitral Hancock valves (n = 209), the linear•
ized stenotic failure rate was 1.1 % per patient-year of fol•
low-up (8 events). The stenotic failure rate was highest in 
the smaller valves (2.1 and 1.4% per patient-year for sizes 
27 and 29 mm, respectively) and lowest in the larger valves 
(0.5 and 0% per patient-year for sizes 31 and 33 mm, re•
spectiveiy). Stenotic failure also related to longer implant 
duration: four failures occurred in the cohort whose valve 
had been in place for 7 to 8 years, three in the cohort 
operated on 5 to 6 years previously, oIle in the 3 to 4 year 
cohort and none in the cohort operated on within the pre•
ceding 2 years. 
Etiology of stenosis. The predominant cause of bio•
prosthetic valve stenosis was extensive leaflet calcification, 
Figure 4. Effective orifice area-flow relation in normal Hancock 
bioprostheses stratIfied by valve size. Solid line connects effective 
orifice area calculated for an individual valve at different flow rates 
under varying conditions (symbols). In general, effective orifice 
area increased as flow increased. The most marked increase was 
observed in the largest valve size (33 mm). 
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Figure 5. Comparison of effective orifice area-flow relation In 
normal (solid symbols) and stenotic (open symbols and asterisks) 
Hancock bioprostheses by valve size. ~ffective orifice area was 
less suitable than gradient for differentiation of abnormal from 
normal function (see text). 
Table 2. Stenotic Failure Rates in 209 Patients After Mitral 
Valve Replacement With a Hancock Porcine Bioprosthesis 
(1976 to 1982) 
StenotIc Failures 
Valve Follow-Up Rate per 
Size No. of (mo)* 100 Patient-
(mm) Patients Mean (range) Events Years 
27 40 43 (I to 78) 3 2 I 
29 78 43 (I to 95) 4 14 
31 67 39 (I to 101) 05 
33 24 36 (I to 86) 0 0 
27 to 33 209 41 (I to 101) 8 1.1 
*Follow-up 96% complete (eight lost). 
which occurred in four (50%) of eight patients. Fibrous 
tissue overgrowth into the inflow orifice and onto the base 
of the leaflets was observed in three (38%) of eight whereas 
prosthetic thrombosis or inward stent bending occurred in 
one (12%) of eight. 
Hemodynamic findings (Table 3). Cardiac catheteriza•
tion before reoperation demonstrated a mean diastolic gra•
dient of 16 ± 8 mm Hg (range 9 to 38) at a mean diastolic 
flow of 152 ± 55 mlls (range 94 to 228), with a calculated 
effective orifice area of 1.0 ± 0.3 cm2 (range 0.5 to 1.5). 
Previously reported cases of stenotic valve failure (Ta•
ble 3). The valve size distribution, interval to explantation, 
pathologic findings and hemodynamics of the eight reported 
abnormal valves (29-34) were similar to those of our own 
eight stenotic bioprostheses. The only statistically signifi•
cant difference was age. Our patients with an abnormal valve 
were older than those reported on previously but were sig•
nificantly younger than the remaining patients at our insti•
tution who did not develop bioprosthetic valve stenosis (p 
< 0.05). Because of the similarity in pathologic and hemo•
dynamic findings, both groups of stenotic bioprostheses were 
pooled for the purpose of comparison with the normal valves. 
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Table 3. Clinical Characteristics of Patients With a Stenotic 
Hancock Mitral Bioprosthesis From Present Series (n = 8) and 
From Literature Review (n = 8) 
PreVIOusly 
Present Reported 
Series Casest 
(n = 8) (n = 8) 
Age at implantation (yr)* 
Mean:!: SD 51 :!: 13 23 :!: 17 
Range 25 to 66 6 to 50 
Valve size (mm) 
27 3 5 
29 4 2 
31 I I 
33 0 0 
Interval to explantation (mo) 
Mean:!: SD 72 :!: 19 51 :!: 33 
Range 39 to 96 4 to 106 
Hemodynamics before explantation 
Mean diastolIc gradient (mm Hg) 
Mean:!: SD 16 ± 8 22 :!: 7 
Range 9 to 38 II to 30 
No. of ,tudles performed 15 8 
Effective orifice area (cm2) 
Mean ± SD 10 :!: 0.3 0.8 :!: 0.3 
Range 0.5 to 1.5 0.5 to 1.3 
No. of stud Ie, performed IS 8 
Mean diastolic flow (mIls) 
Mean:!: SD 152 :!: 55 132:!: 30 
Range 94 to 228 91 to 178 
No. of studies performed 15 8 
Pathologic mode of failure 
Leaflet calcification 4 4 
Fibrous tIssue overgrowth 3 3 
Inward stent bending 0 I 
ThrombosIs 0 
*p < 0.05. present series versus previously reported cases; treferences 
29 to 34. 
Differentiation of pathologic from 
physiologic stenosis 
Abnormal valves had a significantly larger mean gra•
dient, smaller effective orifice area and lower flow than 
normal valves (p < 0.05) (Table 4). However, no single 
value of gradient or effective orifice area completely dif•
ferentiated stenotic front normal valves because of overlap 
in the hemodynamics of these two groups. For example, 
choosing 13 mm Hg as the tipper limit of normal for the 
gradient falsely classified 9 of 23 abnormal measurements 
as normal (39% false negative rate). If the upper limit of 
normal was decreased to 12 or 11 mm Hg, the false negative 
rate was reduced, but the false positive rate (identification 
of normal valves as stenotic) was increased. We believed 
that the diagnostic accuracy of these measurements might 
be improved if flow and valve size were taken into account. 
A linear regression model identified in normal valves a 
statistically significant (p < 0.0001) correlation between 
flow and square root of the gradient; the mean regression 
line was an exponential function when plotted as gradient 
lACC Vol 7. No 2 
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versus flow (Fig. 6). The predicted gradient-flow relation 
was different for each valve size; larger valve sizes dem•
onstrated smaller gradients at equivalent flow rates. The 
mean regression equations for gradient (G) as a function of 
flow in valves of various size were given by the following 
formulas: vG = 0.0079 x flow + 1.08 (27 mm; r = 
0.94, p < 0.0001); vG = 0.0075 x flow + 0.89 (29 
mm; r = 0.78, P < 0.0001); vG = 0.0066 x flow + 
0.93 (31 mm; r = 0.74, P < 0.0001); vG = 0.0040 x 
flow + 1.23 (33 mm; r = 0.76, P < 0.0001). 
Ninety-nine percent confidence limits for gradient as a 
function of flow were constructed from the regression model. 
These confidence limits (dotted lines in Fig. 6) were chosen 
to minimize the misclassification of normal and abnormal 
valves, because it Was perceived that reoperation in patients 
with a normal valve was more harmful than delaying op•
eration in patients with a slightly stenotic valve. All mea•
surements in stenotic valves fell outside the 99% confidence 
limits of the gradient-flow relation for each valve size. and 
all values in normal valves were within these limits (Fig. 
6). Therefore, complete differentiation of stenotic from nor•
mal measurements was achieved, and the misclassification 
rate was reduced to zero. 
A linear regression model identified a significant cor•
relation between effective orifice area and flow (Fig. 5). 
However, there was a greater degree of data scatter than 
occurred for the gradient-flow relation and. as a result, the 
confidence limits were relatively wide and overlapped with 
some of the abnormal values. Accordingly, the effective 
orifice area-flow relation was not suitable for complete dif•
ferentiation of abnormal from normal fUnction. 
Discussion 
Normal bioprosthetic function. Hancock porcine bio•
prostheses are physiologically stenotic valves. In vitro (14-17) 
and in vivo (18-27) studies have demonstrated that Hancock 
bioprostheses produce larger gradients, smaller effective 
orifice areas and larger trans valvular energy losses than me•
chanical tilting disc (Bjork-Shiley, Lillehei-Kaster) and bi•
leaflet (St. Jude) valves of comparable anular dimensions. 
Table 4. Gradient, Effective Orifice Area and Flow in Normal 
and Stenotic Mitral Hancock Bioprostheses 
Mean gradient (mm Hg) 
Mean:!: SD 
Range 
EffectIve orifice area (cm2) 
Mean:!: SD 
Range 
Mean diastolic flow (mIls) 
Mean:!: SD 
Range 
Normal 
(n = 169) 
5.2 ± 2.6 
2.0 to 13.4 
2.3 :!: 0.6 
1.1 to 4.4 
189 :!: 72 
65 to 461 
StenotIc 
(n = 23) 
18.3 ± 7.6 
9.0 to 38.0 
0.9 :!: 0.3 
0.50 to 1.5 
145 :!: 48 
91 to 278 
p 
Value 
< 005 
< 0.05 
< 0.05 
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Figure 6. Comparison of gradient-flow relation In normal and 
stenotic Hancock bioprostheses. stratified by valve size, The dashed 
lines outline the 99% confidence limits of the normal gradient•
flow relation, between which (shaded area) are contained all 169 
measurements from 42 normal valves (solid symbols), Note that 
all 23 measurements in 16 stenotic valves (open symbols and 
asterisks) are above and to the left of the shaded area, 
The reason is that the supporting structures of the Hancock 
valve (sewing ring, struts and muscle shelf) occupy a larger 
proportion of the available anular area, resulting in a smaller 
ratio of the internal to external orifice area 04-17.38), It 
has been anticipated that the larger gradients may be phys•
iologically important, especially in the smaller sizes of the 
Hancock valve (1-3,23), 
In normal mitral Hancock valves, the present study dem•
onstrated mean pressure gradients ranging from 2,0 to 8.4 
mm Hg at mean diastolic flow rates of 65 to 251 mils (Table 
1), Ubago et at. (19) reported a mean gradient of 18,3 mm 
Hg across a normal mitral Hancock valve (size 27 mm) and 
other studies (18-27) have documented a wide range of 
normal gradients, Because flow rates as high as 419 mlls 
occur under baseline conditions (19), we performed incre•
mental epicardial pacing (22) and isoproterenol infusion (24) 
to extend the range of flows over which observations were 
made, and to determine whether an increase in flow produced 
an increase in mean gradient in vivo. Our study demon•
strated that interventions that increased flow led to an in•
crease in gradient; isoproterenol infusion generally produced 
the largest increment in mean diastolic flow and mean gra•
dient (Table 1). On an individual basis, incremental in•
creases in flow were accompanied by incremental increases 
in mean gradient. regardless of the type of intervention 
(Fig. 2). 
A mathematical model that correlated mean diastolic flow 
with the square root of the gradient fit the data well (r = 
0.74 to 0.94. P < 0.0001) after significant differences ac•
cording to valve size were accounted for (Fig. 1 and 6). 
This allowed determination and construction of the confi•
dence limits of the normal gradient-flow relation in vivo for 
each valve size. Importantly, all normal values obtained in 
this study fell within these confidence limits (Fig. 6). 
Effective orifice area increased with higher flow rates 
(Fig. 4 and 5). after differences due to valve size were 
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accounted for (Fig. 3). Previous in vitro and in vivo studies 
(14,17.19) have corroborated these findings. Wright (15) 
demonstrated that the mitral Hancock valve does not open 
fully until peak pulsatile flow exceeds 165 to 238 mils (for 
sizes 27 to 33 mm). At lower peak pulsatile flow rates. the 
valve remains incompletely open throughout diastole. At 
higher peak pulsatile flow rates. the valve opens fully only 
during that part of diastole in which the flow rates exceed 
these threshold levels. Thus. leaflet pliability determines the 
extent and duration of maximal leaflet opening. 
Phasic variations in orifice size are apparent throughout 
diastole when bioprostheses are photographed by high-speed 
cinematography (14,15). Porcine bioprostheses therefore 
behave as dynamic rather than static orifices. Fisher et aI. 
(39) emphasized the need to adjust for variations in size 
during phasic mitral flow to obtain the mean orifice area. 
Viscous effects (15.17) contribute another source of vari•
ation of effective orifice area with flow. These effects are 
most prominent at low flow rates, where they add to the 
pressure gradient and reduce effective orifice area. At very 
high flows. their contribution is negligible. Thus. when 
viscous effects are accounted for, effective orifice area grad•
ually increases with flow, eventually reaching a plateau as 
the orifice area approaches a certain limit (17). 
The discharge coefficient utilized in the Gor/in relation 
is very close to 1 for nearly all bioprostheses (15. I 7), but 
may vary with flow and gradient. especially at the extremes 
of flow. Therefore. the use of a fixed constant in the cal•
culation of mean effective orifice area may lead to significant 
errors in estimation of the true orifice area. Indeed. a greater 
degree of data scattering and smaller correlation coefficients 
were observed in the effective orifice area-flow relation (Fig. 
5) compared with the gradient-flow relation. In addition. 
because effective orifice area is a calculated (not measured) 
entity. errors are compounded. Because of all these con•
siderations, the effective orifice area-flow relation was not 
suitable for establishment of normal limits. 
Bioprosthetic stenosis. In pathologic studies of of por•
cine bioprostheses removed at surgery or necropsy (4-11), 
calcification was the most common degenerative process 
leading to valve dysfunction. The two principal sites of 
calcification were the connective tissue and the cusps (par•
ticularly along the collagen fibrils in the spongiosa), and 
small thrombi on the surface of the cusps (6). These calcific 
deposits caused cuspal stiffening and ultimately stenosis, or 
collagen disruption leading to possible tears and regurgi•
tation. Bioprosthetic stenosis, although most commonly 
caused by calcification, may also result from thrombosis, 
fibrous tissue overgrowth, large vegetations and strut creep 
(9,10,12,13,29-34). 
In long-term follow-up of large patient series (40-43). 
bioprosthetic valve degeneration has occurred at a rate of 2 
to 3% per patient-year, with an actuarial freedom from de•
generation of 71 to 79% at 10 years. Higher rates of tissue 
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failure have been observed in younger age groups, especially 
children (40.43-48), and in valves that have been implanted 
for more than 5 years (\ 2.42). Bioprostheses demonstrate 
more severe pathologic changes and a higher incidence of 
failure in the mitral than in the aortic position; this may be 
due to a larger pressure difference and a greater tensile stress 
on the cusps when closed. and more frequent flexion when 
open (twice per cycle) compared with the aortic position 
(12.49-51). 
In the present study of209 recipients of a Hancock mitral 
valve followed up for up to 8.5 years. the stenotic failure 
rate was 1.1 % per patient-year. This stenotic failure rate 
was related inversely to valve size, being four times more 
likely in the 27 mm than in the 31 mm valve (Table 2). 
Thus, the larger gradients and less efficient hemodynamic 
performance of the smaller valves translated into a higher 
risk of stenotic failure. It may be logically concluded that 
a small mitral anulus is a relative contraindication to the 
use of a bioprosthesis. 
Each of the eight stenotic bioprostheses described in this 
report underwent explantation and pathologic examination. 
The predominant mode of failure was leaflet calcification 
(Table 3). which has been the experience at other centers 
(4-13,40-49). In comparison with the eight patients in pub•
lished reports of pathologically confirmed bioprosthetic ste•
nosis accompanied by preoperative catheterization studies 
(29-34). the eight patients in our study were older, but 
otherwise had a similar valve size distribution, interval to 
explantation, hemodynamic profile before explantation and 
pathologic mode of failure. Thus, our experience with bio•
prosthetic stenosis was quite similar to that previously 
reported. 
Hemodynamic differentiation of pathologic from 
physiologic stenosis. Given the wide range of gradients 
that may be found with normally functioning Hancock bio•
prostheses. and the small gradients that may occur in stenotic 
valves at low flow rates. hemodynamic differentiation of 
pathologic from physiologic stenosis on the basis of a single 
value of gradient or effective orifice area may be difficult. 
The cost of an incorrect diagnosis is likely to be quite high: 
the patient with an incorrect diagnosis of prosthetic stenosis 
may undergo an unnecessary operation with attendant mor•
bidity and mortality, while the patient incorrectly judged to 
have a normal valve may have unexplained severe symptoms 
for many years. Furthermore, as the time interval from 
implantation increases, a greater number of patients may be 
expected to come to medical attention because of suspected 
bioprosthetic stenosis (42). 
Importantly, the normal gradient-flow relation, when 
stratified by valve size (Fig. 6), completely differentiated 
stenotic from normally functioning valves. These limits, 
established early postoperatively during the first 2 years of 
our experience with the Hancock valve, were prospectively 
validated by comparison with data on stenotic bioprostheses 
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later obtained from our own patient group (minimal interval 
to explantation, 3 years) and from previously reported cases 
(29-34), all of which had hemodynamic values outside the 
normal gradient-flow limits. 
The effective orifice area-flow relation provided less re•
liable discrimination (Fig. 5) because of a greater degree of 
data scattering in normal valves. This variability in the ef•
fective orifice area-flow relation might be decreased by tak•
ing into account the gradient- or flow-dependence of the 
Gorlin constant (52), but this approach has not been vali•
dated in porcine bioprostheses under conditions of phasic 
mitral flow. The equation for adjustment of the Gorlin con•
stant is likely to be different in stenotic and normal prostheses 
(52), a distinction that is usually not known a priori. Errors 
in gradient or flow determination will be compounded by 
such an adjustment in the calculation of effective orifice 
area. For all of these reasons, we have found that the gra•
dient-flow relation is a better discriminator between normal 
and stenotic function than is the effective orifice area-flow 
relation. 
Lipson et al. (53) reported a significant increase in mean 
gradient and decrease in effective orifice area as determined 
by cardiac catheterization in 18 patients with a Hancock 
mitral valve in place for more than 5 years. Only one of 
these patients underwent reoperation. explantation and 
pathologic examination of the prosthesis. Whether most of 
these patients simply developed progressive cuspal stiff•
ening due to increasing leaflet thickness (54.55) or whether 
they developed true pathologic stenosis due to extensive 
leaflet calcification, thrombosis or strut creep cannot be 
determined from their study. In the single patient who under•
went reoperation. pathologic stenosis due to strut creep was 
identified: the preoperative hemodynamic measurements 
(mean gradient 12 mm Hg: flow 158 mils: size 29 mm) 
were clearly outside the normal range established in our 
study. Although cuspal stiffening may theoretically be prob•
lematic for the definition of normal hemodynamics. the choice 
of 99% confidence limits (as in our study) probably results 
in the classification of all such patients as . 'normal." Such 
a classification may be justified. given the risks of reoper•
ation in these patients with minimally abnormal valves. 
Role of alternative diagnostic approaches. Biopros•
thetic valve stenosis cannot be reliably assessed by history, 
physical examination or current noninvasive techniques (1,53). 
Spectral phonocardiographic changes in the peak frequency 
of the first heart sound may be a manifestation of leaflet 
stiffening or stenosis (56), but the accuracy and reproduc•
ibility of the technique are unknown and its validity has not 
been established by pathologic examination of large num•
bers of excised bioprostheses. Similarly, two-dimensional 
echocardiographic assessment of bioprosthetic mitral valve 
stenosis is not reliable: significant stenosis may be missed, 
and stenosis may be falsely identified when not present (57). 
Doppler ultrasound techniques provide a noninvasive es•
timation of blood flow velocity and pressure gradients across 
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bioprosthetic valves (58-60), and this method appears 
promising in the evaluation of bioprosthetic valve stenosis. 
However, such gradients measured across normal and ste•
notic valves may demonstrate sizable overlap (60). The 
results of the present study suggest that such measurements 
will not be very useful in distinguishing abnormal from 
normal function unless measurement of transvalvular flow 
is available. Unfortunately, significant technical problems 
remain with Doppler-derived cardiac output determinations 
(39). Pressure half-time may provide an improved Doppler 
assessment of prosthetic stenosis, but experience with this 
technique in mitral valve bioprostheses has been limited and 
requires further evaluation (59). 
We gratefully acknowledge the secretanal assistance of Helen Scharnroth 
and Kathie Farrington. GraphiC illustrations were provided by Lance 
LaForteza 
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